QUOTED. April 23, 2018. Larry Biegelsen.
Check out what Wells Fargo analyst Larry Biegelsen had to say about why a global patent battle between Edwards Lifesciences and Boston Scientific on transcatheter aortic valve replacements will likely end in settlement.
"[Boston Scientific] appears to have the upper hand in Europe (at least at the moment), while [Edwards] appears to have a position of strength in the US based on the favorable IPR decision against BSX’s '608 patent this past March." – Larry Biegelsen, senior medical device analyst, Wells Fargo
- Find out more: Boston Sci Wins Latest TAVR Patent Dispute Against Edwards
Click here for a free trial of Medtech Insight